Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | HTR2B | P41595 | 5/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543688 | 1.00 | MTNR1A (0.38) | MTNR1AMTNR1BHTR2CHTR2BMAOA | |
| SCHEMBL10257990 | 0.87 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL543365 | 0.87 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL543364 | 0.87 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL543471 | 0.86 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL543472 | 0.86 | HTR2C (0.51) | HTR2CHTR2BHTR2A | |
| SCHEMBL543880 | 0.84 | MTNR1A (0.38) | MTNR1AMTNR1BHTR2CHTR2BMAOA | |
| SCHEMBL2776905 | 0.82 | MTNR1A (0.43) | MTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL2778912 | 0.82 | MTNR1A (0.43) | MTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL543299 | 0.82 | MTNR1A (0.50) | MTNR1AMTNR1BMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141150-B1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | MTNR1A 1/4885MTNR1B 2/4885HTR2C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.